| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 9, 2021 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2021 | $5.00 | Buy | HC Wainwright & Co. |
| 11/9/2021 | $7.00 | Buy | Jefferies |
| 9/24/2021 | $6.00 | Overweight | Cantor Fitzgerald |
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in February 2022 -- -- Company to host video webcast at 8:30am ET on January 19, 2022 -- BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("OSMT" or the "Company"), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL"). This rebranding reflects RVL's strategy to become a growth comp
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James "JD" Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates. Dr. Jackie Yee is board-certified in Plastic and Reconstructive Surgery and speciali
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows: Date:Wednesday, January 19, 2022Time:8:30 a.m. ETWebcast:https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome The webcast will be available thereafter via the Company's website at www.rvlpharma.com under the "Investor & News
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
EFFECT - Osmotica Pharmaceuticals plc (0001739426) (Filer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
HC Wainwright & Co. initiated coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $5.00
Jefferies resumed coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $7.00
Cantor Fitzgerald initiated coverage of Osmotica Pharmaceuticals with a rating of Overweight and set a new price target of $6.00
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: DateMonday, November 15, 2021Time4:30 p.m. ETToll free (U.S.)(866) 672-5029International(409) 217-8312Conference ID57399556Webcast (live and replay)www.osmotica.com under the "Investor & News" section
BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial results on Monday, August 16, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: Date Monday, August 16, 2021Time 4:30 p.m. ETToll free (U.S.) (866) 672-5029International (409) 217-8312Conference ID 1278168Webcast (live and replay) www.osmotica.com under the "Investor &
SC 13D/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)
SC 13G - Osmotica Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)